F-star Therapeutics Common Stock

The latest common stock for FSTX is $2K as of September 2022. That compares with $2K in the prior-year period — up 0.0% year over year. Investors often review this figure alongside F-star Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, FSTX's common stock moved from $2K to $2K — essentially flat versus a year earlier. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in F-star Therapeutics's operating scale or balance-sheet position.

A common stock figure of $2K for FSTX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting FSTX's common stock ($2K), review year-over-year change from $2K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack F-star Therapeutics's common stock against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.